IBS Treatment Companies
In the realm of gastrointestinal health, IBS Treatment companies specialize in developing therapies and interventions for irritable bowel syndrome (IBS). These organizations contribute to
Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
Latest Irritable Bowel Syndrome (IBS) Treatment Companies Updates:
Ironwood Pharmaceuticals: Promising Phase 3 data for Linzess (linaclotide) in adult IBS-C patients with constipation-predominant symptoms, potentially expanding treatment options.
Takeda Pharmaceuticals: Positive Phase 2a results for TAK-786, a novel oral guanylate cyclase-C (GC-C) stimulator, showing potential for treating both IBS-C and IBS-D.
Allergan: Launched a Phase 2 study for AG041270, a new investigational therapy targeting neurokinin-1 (NK-1) receptors, for treating IBS-D.
AstraZeneca: Received FDA approval for Trinessa (drospirenone, ethinyl estradiol, and levofloxacin) for treating moderate-to-severe IBS-C in women with endometriosis.
Suven Therapeutics: Launched SB207798, a first-in-class, peripherally acting G-protein coupled receptor 54 (GPR54) agonist, for treating CIC in adults, which could potentially be repurposed for IBS in the future.
Synergy Pharmaceuticals: Expanded market access for Trulance (plecanatide) in Canada for treating adults with IBS-C.
List of Irritable Bowel Syndrome (IBS) Treatment Key companies in the market:
- Allergan Plc (Ireland)
- Sucampo Pharmaceuticals (U.S.)
- Ironwood Pharmaceuticals, Inc. (U.S.)
- Astellas Pharma Inc. (Japan)
- Valeant Pharmaceuticals (Canada)
- Abbott Laboratories (U.S.)
- Synergy Pharmaceuticals, Inc. (U.S.)
- Ardelyx, Inc. (U.S.)
- Nestle (Switzerland)
- Sebela Pharmaceuticals (Ireland)
- Probi (Sweden)
- Alfasigma USA, Inc. (Italy)
IBS Treatment Market Highlights:
IBS Treatment Market Highlights:
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
